Principal Financial Group’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$57.7M Buy
106,561
+4,869
+5% +$2.74M 0.03% 476
2026
Q1
$60.3M Buy
101,692
+3,534
+4% +$1.76M 0.03% 429
2025
Q4
$47.8M Sell
98,158
-7,609
-7% -$3.54M 0.02% 482
2025
Q3
$44.3M Sell
105,767
-5,583
-5% -$1.88M 0.02% 508
2025
Q2
$32M Sell
111,350
-511
-0.5% -$153K 0.02% 612
2025
Q1
$34.5M Buy
111,861
+309
+0.3% +$106K 0.02% 555
2024
Q4
$39.4M Sell
111,552
-921
-0.8% -$339K 0.02% 540
2024
Q3
$40.3M Sell
112,473
-44,683
-28% -$15.1M 0.02% 537
2024
Q2
$50.1M Sell
157,156
-25,835
-14% -$6.84M 0.03% 463
2024
Q1
$42M Buy
182,991
+4,655
+3% +$1.05M 0.02% 540
2023
Q4
$39.2M Sell
178,336
-614
-0.3% -$142K 0.03% 529
2023
Q3
$40.4M Sell
178,950
-2,722
-1% -$627K 0.03% 481
2023
Q2
$40.1M Buy
181,672
+1,341
+0.7% +$297K 0.03% 501
2023
Q1
$40.4M Sell
180,331
-112,916
-39% -$27.8M 0.03% 501
2022
Q4
$81.5M Buy
293,247
+114,114
+64% +$28.8M 0.06% 272
2022
Q3
$37.5M Sell
179,133
-112,086
-38% -$25.1M 0.03% 470
2022
Q2
$68.6M Buy
291,219
+138,171
+90% +$28.1M 0.05% 310
2022
Q1
$27.5M Buy
153,048
+66
+0% +$12.6K 0.02% 715
2021
Q4
$33.1M Sell
152,982
-2,140
-1% -$420K 0.02% 622
2021
Q3
$28.6M Sell
155,122
-637
-0.4% -$125K 0.02% 670
2021
Q2
$27.9M Buy
155,759
+2,685
+2% +$511K 0.02% 712
2021
Q1
$25.6M Buy
153,074
+21,527
+16% +$3.59M 0.02% 736
2020
Q4
$20M Sell
131,547
-464
-0.4% -$60.9K 0.01% 774
2020
Q3
$13.3M Sell
132,011
-3,666
-3% -$402K 0.01% 897
2020
Q2
$16.4M Sell
135,677
-31,141
-19% -$3.5M 0.01% 758
2020
Q1
$15.8M Sell
166,818
-55,271
-25% -$5.25M 0.02% 651
2019
Q4
$19.6M Buy
222,089
+32,242
+17% +$2.84M 0.02% 813
2019
Q3
$15.1M Sell
189,847
-3,282
-2% -$264K 0.01% 970
2019
Q2
$15.1M Buy
193,129
+386
+0.2% +$36.1K 0.01% 989
2019
Q1
$22.6M Buy
192,743
+1,724
+0.9% +$201K 0.02% 680
2018
Q4
$20.8M Sell
191,019
-2,989
-2% -$347K 0.02% 678
2018
Q3
$24.8M Buy
194,008
+2,134
+1% +$264K 0.02% 716
2018
Q2
$21.7M Sell
191,874
-4,359
-2% -$479K 0.02% 775
2018
Q1
$22M Buy
196,233
+5,396
+3% +$685K 0.02% 731
2017
Q4
$28.2M Buy
190,837
+6,096
+3% +$775K 0.03% 620
2017
Q3
$21.6M Sell
184,741
-5,724
-3% -$731K 0.02% 725
2017
Q2
$24.7M Buy
190,465
+7,126
+4% +$889K 0.02% 652
2017
Q1
$24.8M Buy
183,339
+14,197
+8% +$2.15M 0.03% 595
2016
Q4
$24.3M Sell
169,142
-1,688
-1% -$216K 0.03% 589
2016
Q3
$20.2M Buy
170,830
+2,558
+2% +$307K 0.03% 650
2016
Q2
$17.8M Buy
168,272
+15,907
+10% +$1.77M 0.02% 690
2016
Q1
$17M Buy
152,365
+6,325
+4% +$800K 0.02% 670
2015
Q4
$22.9M Buy
146,040
+4,184
+3% +$609K 0.03% 502
2015
Q3
$18.6M Sell
141,856
-386
-0.3% -$61.9K 0.03% 576
2015
Q2
$24.7M Buy
142,242
+4,060
+3% +$730K 0.04% 487
2015
Q1
$23.8M Buy
138,182
+2,727
+2% +$416K 0.04% 471
2014
Q4
$17.5M Buy
135,455
+959
+0.7% +$124K 0.03% 595
2014
Q3
$17.3M Buy
134,496
+10,971
+9% +$1.13M 0.03% 579
2014
Q2
$10.9M Sell
123,525
-4,215
-3% -$405K 0.02% 873
2014
Q1
$12M Sell
127,740
-225,076
-64% -$23M 0.02% 788
2013
Q4
$39.9M Buy
352,816
+232,323
+193% +$20.9M 0.07% 309
2013
Q3
$9.5M Sell
120,493
-5
-0% -$365 0.02% 838
2013
Q2
$7.93M Buy
+120,498
New +$7.76M 0.02% 899

Other funds holding UTHR

Principal Financial Group's UTHR Position: Q2 2026 in Review

Principal Financial Group increased its United Therapeutics (UTHR) stake by 4.8% in Q2 2026, buying an estimated $2.74M and bringing the position to 106,561 shares worth $57.7M. The position accounts for 0.03% of the portfolio, ranked #476.

Principal Financial Group first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $81.5M in Q4 2022. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Principal Financial Group held 106,561 shares of United Therapeutics worth $57.7M as of Q2 2026.
  • Principal Financial Group bought 4,869 United Therapeutics shares in Q2 2026, an estimated $2.74M.
  • United Therapeutics made up 0.03% of Principal Financial Group's portfolio in Q2 2026, its #476 holding.
  • Principal Financial Group first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Principal Financial Group's United Therapeutics position peaked at $81.5M in Q4 2022.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.